Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
03 janv. 2023 08h00 HE
|
Daxor Corporation
Study Shows Direct Volume Measurement’s Accuracy Compared to Pressure Measures Oak Ridge, TN, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
15 nov. 2022 08h45 HE
|
Daxor Corporation
Oak Ridge, TN, Nov. 15, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of...
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
14 nov. 2022 17h03 HE
|
Daxor Corporation
Oak Ridge, TN, Nov. 14, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has...
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs
10 nov. 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be...
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
03 nov. 2022 08h00 HE
|
Daxor Corporation
Study Highlighted That Only The BVA-100 Accurately Measures Volume Derangements Compared to Commonly Used Surrogates Oak Ridge, TN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq:...
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
31 oct. 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart...
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
05 oct. 2022 08h30 HE
|
Daxor Corporation
Evidence Presented Utilizing Daxor’s BVA-100® Blood Volume Test Oak Ridge, TN, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
04 oct. 2022 08h30 HE
|
Daxor Corporation
The Premier Event For The Cardiovascular Industry's Leading Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically Improve Their Business and...
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
04 oct. 2022 08h00 HE
|
Daxor Corporation
Traditional Care: More than 50% Discharged From Hospital With Suboptimal Treatment Oak Ridge, TN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood...
New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
03 oct. 2022 09h00 HE
|
Daxor Corporation
Patients Receiving BVA Stayed 2.5 Fewer Days in Hospital Resulting in Reduced Costs of Care Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation, the global leader in blood volume...